BamSEC and AlphaSense Join Forces
Learn More

BioAtla Inc.

NASDAQ: BCAB    
Share price (12/23/24): $0.61    
Market cap (12/23/24): $29.5 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 27 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 58 pages Global Transaction Agreement
12/34/56
EX-10.1
from 8-K 52 pages License Agreement
12/34/56
EX-10.2
from 10-Q 5 pages Restricted Stock Unit Agreement Under the Bioatla, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 3 pages Bioatla, Inc. Director Compensation Policy
12/34/56
EX-10.2
from 10-Q 6 pages Restricted Stock Unit Agreement Under the Bioatla, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 15 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[***].” China Clinical Trial Services Agreement
12/34/56
EX-10.25
from 10-K 8 pages Stock Option Agreement Under the Bioatla, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.24
from 10-K 8 pages Stock Option Agreement Under the Bioatla, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.17
from 10-K 18 pages First Amendment to Lease
12/34/56
EX-10.3
from 10-Q 6 pages Restricted Stock Unit Agreement Under the Bioatla, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.2
from 10-Q 6 pages Restricted Stock Unit Agreement Under the Bioatla, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 10 pages Stock Option Agreement Under the Bioatla, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10
from 10-K 3 pages Bioatla, Inc. Director Compensation Policy
12/34/56
EX-10
from 10-K 4 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[***]. First Amendment to Master Clinical Trial Collaboration Agreement
12/34/56
EX-10.2
from 10-Q 45 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[***].” Master Clinical Trial Collaboration Agreement
12/34/56
EX-10.1
from 8-K 18 pages Bioatla, Inc. Management Change of Control Severance Plan and Summary Plan Description Bioatla, Inc. Management Change of Control Severance Plan and Summary Plan Description
12/34/56
EX-10.1
from 10-Q 9 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[***].” China Clinical Trial Services Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Bioatla, Inc. Director Compensation Policy
12/34/56
EX-10.31
from 10-K 3 pages Bioatla, Inc. Director Compensation Policy
12/34/56